Yale recognizes vital role of Bristol-Myers Squibb in biomedical research and education

October 07, 2004

New Haven, Conn. -- The Yale School of Medicine recently hosted a special program of neuroscience lectures and unveiled a plaque at the heart of the medical campus to honor Bristol-Myers Squibb Company for its contributions to biomedical research and education at Yale. University President Richard Levin and Dean Robert Alpern hosted Peter Dolan, Chairman and CEO of Bristol-Myers Squibb, and a contingent of the company's senior executives.

Levin unveiled the plaque, located a few steps from the Dean's Office in Sterling Hall of Medicine, together with Dolan, John Damonti, President of the Bristol-Myers Squibb Foundation, and Francis Cuss, Senior Vice President for Drug Discovery, who directs the company's research complex in Wallingford, CT.

"Bristol-Myers Squibb is one of Yale's oldest and most important corporate relationships in advancing biomedical research and education," President Levin said. "When I joined the faculty 30 years ago, Bristol-Myers was already supporting research in the Department of Human Genetics, which had just been established." Levin attributed the partnership's longevity to a shared sense of purpose: "Over the years, we have come to recognize in each other a strong belief in the power of science to improve human health and well-being."

Dean Alpern noted that Bristol-Myers Squibb has played an instrumental role in creating and developing Yale's Combined Program in the Biological and Biomedical Sciences, launched in 1996 to restructure graduate education in the life sciences. "Without Bristol-Myers Squibb's vision -- and the great commitment and generosity behind it -- the Combined Program would not have been possible," Alpern said.

Before the unveiling ceremony, the guests joined Yale students and faculty to hear two lectures on new developments in neuroscience research. Robert Zaczek, Director of Biochemical Pharmacology in Bristol-Myers Squibb's Neuroscience Biology unit, discussed the shift from empirical to molecular approaches in the neuroscience drug discovery process.

Pasko Rakic, the Dorys McConnell Duberg Professor of Neuroscience, surveyed the logistics of brain development, drawing on his groundbreaking research on the molecular mechanisms of neuronal cell proliferation and migration. Professor Rakic is Chairman of the Department of Neurobiology at the School of Medicine and Director of the Kavli Institute for Neuroscience at Yale University. In 2002, Professor Rakic was the recipient of Bristol-Myers Squibb's Award for Distinguished Achievement in Neuroscience. In addition to innovation in graduate education and genetics research, Bristol-Myers Squibb has supported a broad range of biomedical education and research activities at Yale.

New approaches to cancer therapeutics, the molecular biology of substance abuse and depression, medicines to combat HIV, and insulin resistance in Type 2 diabetes are just a few of the areas of inquiry in which Bristol-Myers Squibb has boosted the efforts of Yale researchers.

Current areas of collaboration between Bristol-Myers Squibb and Yale include the Combined Program, the company's Secure the Future initiative -- a program of grants for local responses to the HIV pandemic in Southern and West Africa -- and a project at the Yale School of Nursing to develop best practice guidelines for treating chronic wounds, such as ulcers.
-end-


Yale University

Related Neuroscience Articles from Brightsurf:

Researchers rebuild the bridge between neuroscience and artificial intelligence
In an article in the journal Scientific Reports, researchers reveal that they have successfully rebuilt the bridge between experimental neuroscience and advanced artificial intelligence learning algorithms.

The evolution of neuroscience as a research
When the first issue of the JDR was published, the field of neuroscience did not exist but over subsequent decades neuroscience has emerged as a scientific field that has particular relevance to dentistry.

Diabetes-Alzheimer's link explored at Neuroscience 2019
Surprising links exist between diabetes and Alzheimer's disease, and researchers are beginning to unpack the pathology that connects the two.

Organoid research revealed at Neuroscience 2019
Mini-brains, also called organoids, may offer breakthroughs in clinical research by allowing scientists to study human brain cells without a human subject.

The neuroscience of autism: New clues for how condition begins
UNC School of Medicine scientists found that a gene mutation linked to autism normally works to organize the scaffolding of brain cells called radial progenitors necessary for the orderly formation of the brain.

Harnessing reliability for neuroscience research
Neuroscientists are amassing the large-scale datasets needed to study individual differences and identify biomarkers.

Blue Brain solves a century-old neuroscience problem
In a front-cover paper published in Cerebral Cortex, EPFL's Blue Brain Project, a Swiss Brain Research Initiative, explains how the shapes of neurons can be classified using mathematical methods from the field of algebraic topology.

Characterizing pig hippocampus could improve translational neuroscience
Researchers have taken further steps toward developing a superior animal model of neurological conditions such as traumatic brain injury and epilepsy, according to a study of miniature pigs published in eNeuro.

The neuroscience of human vocal pitch
Among primates, humans are uniquely able to consciously control the pitch of their voices, making it possible to hit high notes in singing or stress a word in a sentence to convey meaning.

Study tackles neuroscience claims to have disproved 'free will'
For several decades, some researchers have argued that neuroscience studies prove human actions are driven by external stimuli -- that the brain is reactive and free will is an illusion.

Read More: Neuroscience News and Neuroscience Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.